Where to buy Cagrilintide in the UK: no licensed source exists, and the sellers with a verifiable COA
Cagrilintide is Novo Nordisk's amylin analogue. It is not approved in any country, alone or combined with semaglutide as CagriSema, so no UK pharmacy can sell it and every vial on offer is unlicensed research material. If you are buying it anyway, the only thing you can check is the certificate: the newest verifiable Cagrilintide certificate on any UK seller's website is on Peptology Labs (peptologylabs.uk), analysed 4 Sep 2026 (task #229652 on Janoshik's site); 4 verified sellers hold one covering Cagrilintide, listed newest first below. It is an investigational compound not licensed for sale or prescription in the UK, not a research peptide, so it sits in a tighter legal category The Peptide Watch does not list vendors for and does not endorse buying outside a prescription.
Who holds the newest Cagrilintide report (4 verified UK sellers)
| Seller | Newest Cagrilintide report | Age of that report | |
|---|---|---|---|
| Peptology Labs peptologylabs.uk | 4 Sep 2026 | 1 month, 16 days | verify |
| BioVanta Research biovantaresearch.com | 25 May 2026 | 4 months, 25 days | verify |
| Clinicore clinicore.co.uk | 16 Jan 2026 | 9 months, 4 days | verify |
| Xlpeptides xlpeptides.com | 13 Nov 2025 | 11 months, 7 days | verify |
Newest report first. Every report was opened on Janoshik's own website and names the seller as the client. The date is the analysis date printed on the report. The verify link opens the laboratory, never the shop. Audit findings, not recommendations.
A record of paperwork, not a recommendation: The Peptide Watch sells nothing, takes no money from sellers and links to none of them.
Why the date matters · What purity means · What Cagrilintide is · Regulators · Every report
Every Cagrilintide purity report we have read (4), one row per report
The 4 verifiable Cagrilintide certificates we have read, newest first
Each row was opened on Janoshik's own site by a real page load and transcribed. The client column is the name the laboratory printed; a certificate counts as a seller's own only when that name is the seller. The report date is the analysis date printed on the report where we have read it, otherwise the date the laboratory received the sample. The verify link opens the laboratory, never the shop. Audit findings, not recommendations.
| Seller | Task | Client on the report | Report date | Result | Batch | |
|---|---|---|---|---|---|---|
| Peptology Labs | #229652 | PEPTOLOGY LABS LTD | 4 Sep 2026 | Cagrilintide · 9.53 mg · 99.906% | CG3979 | verify |
| BioVanta Research | #153888 | Biovanta Research | 25 May 2026 | Cagrilintide · 4.94 mg · 99.735% | CGR-274HJ | verify |
| Clinicore | #99970 | clinicore | 16 Jan 2026 | Cagrilintide · 5.62 mg · 99.446% | cag5-101 | verify |
| Xlpeptides | #88426 | XL Peptides | 13 Nov 2025 | Cagrilintide · 12.23 mg · 99.801% | 250CAG | verify |
Why the date on a certificate matters
What a purity figure means
The purity on a Janoshik report is the share of the main peak in an HPLC chromatogram. 99.5% means that 99.5% of what the detector saw was one substance and 0.5% was something else. It is not the amount in the vial: that is the separate quantity line, in milligrams. It does not by itself prove which substance the peak is: that is identity, confirmed by mass spectrometry. And it says nothing about sterility, endotoxins or heavy metals, which are separate tests.
A purity figure printed on a shop page with no report behind it is a claim, not a measurement. Between two reports, the difference that matters is rarely 99.2% against 99.8%; it is whether the report exists at all, names the seller as the client, covers this compound on its own, and is recent.
What Cagrilintide is, and what it is sold as
Cagrilintide is a long-acting amylin analogue. Cagrilintide is Novo Nordisk's amylin analogue. It is not approved in any country, alone or combined with semaglutide as CagriSema, so no UK pharmacy can sell it and every vial on offer is unlicensed research material.
| Development status | Under regulatory review. FDA review of CagriSema, cagrilintide with semaglutide, since December 2025; not approved in any country. |
|---|---|
| Originator | Novo Nordisk A/S (AM833, NNC0174-0833). Rights: Novo Nordisk A/S. |
| Registered clinical trials | 44 on ClinicalTrials.gov |
An amylin analogue that exists mainly as half of a combination. Novo Nordisk developed cagrilintide to be given with semaglutide as CagriSema. PubMed indexes 117 papers and 18 clinical-trial reports; all 44 registered trials on ClinicalTrials.gov are Novo Nordisk's.
Filed, not approved. Novo Nordisk submitted CagriSema to the FDA in December 2025 on the REDEFINE 1 and 2 trials, in which the combination produced a mean 22.7% weight reduction at 68 weeks; a head-to-head trial against tirzepatide did not show non-inferiority. No regulator had approved it as of September 2026.
Cagrilintide alone has no approved use anywhere. A UK vial of cagrilintide is a copy of an investigational molecule; the only checkable fact about it is a certificate that names the seller and verifies on the laboratory's site.
The published record in numbers, and the sources
| Papers on PubMed | 117 |
|---|---|
| Indexed as rat or mouse studies | 18 |
| Indexed as clinical trials | 18 |
| Published since 2020 | 96 |
Counts are from PubMed on 15 September 2026 using the queries recorded in our evidence file. A description of the published record, not medical advice and not an argument for or against use.
- Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1. (Diabetes Obes Metab, 2026, PMID 42503495)
- Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial. (Lancet Gastroenterol Hepatol, 2026, PMID 42456707)
- Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. (Lancet Diabetes Endocrinol, 2026, PMID 42251860)
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. (Lancet Diabetes Endocrinol, 2026, PMID 42251859)
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. (BMJ, 2024, PMID 38286487)
- The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. (Expert Opin Investig Drugs, 2025, PMID 40022548)
- Weight management treatment in obesity. (Med Clin (Barc), 2025, PMID 40865172)
- BioSpace, Novo Nordisk files for FDA approval of CagriSema
- PharmExec, REDEFINE 4 result against tirzepatide
What regulators say about Cagrilintide
In the UK. Not licensed in the UK. An unlicensed medicine; sold as a research chemical.
We hold no statement from the FDA, MHRA or EMA specifically about Cagrilintide on file. Its development and licence sources are listed under the record above.
What the 4 Cagrilintide certificates show
We have read 4 Janoshik reports covering Cagrilintide, published by 4 UK sellers. Each was opened on Janoshik's own website. All 4 name the seller itself as the client. 2 of the 4 are dated within the last six months. The newest is dated 4 Sep 2026 and the oldest 13 Nov 2025.
All 4 reports give a purity figure for Cagrilintide. The figures run from 99.446% to 99.906%, and all 4 are at 99% or above. A purity figure describes the sample the laboratory received, not every vial from that batch.
Read directly from the newest reports: Peptology Labs: task #229652, sample received 4 Sep 2026, 9.53 mg recovered at 99.906%, client PEPTOLOGY LABS LTD; BioVanta Research: task #153888, analysed 25 May 2026, 4.94 mg recovered at 99.735%, client Biovanta Research; Clinicore: task #99970, analysed 16 Jan 2026, 5.62 mg recovered at 99.446%, client clinicore.
A certificate is a batch document. The lines that matter are the compound (it must say Cagrilintide, not only a batch code), the client (the shop, not its supplier) and the analysis date. A new batch is untested until a new report appears.
Questions people ask
Which UK sellers publish a verifiable Janoshik certificate naming Cagrilintide?
As of 20 October 2026, 4: Peptology Labs, BioVanta Research, Clinicore, Xlpeptides. Each has a report on Janoshik's own website that names the seller as the client and lists Cagrilintide. That is a statement about paperwork, not a recommendation; The Peptide Watch does not recommend anywhere to buy Cagrilintide.
How recent is the newest Cagrilintide certificate from a UK seller?
The newest we have read is Janoshik task #229652, sample received 4 Sep 2026. It is published by Peptology Labs and names it as the client. A certificate covers one batch, so an old one says little about stock on sale today.
How do I check that a certificate for Cagrilintide is genuine?
Four things: an independent laboratory is named; the client field names the seller you are buying from, not a supplier; the compound line says Cagrilintide; and the report's task number and key open the same report on the laboratory's own website (verify.janoshik.com). A branded PDF with no laboratory name and no verification code fails on the first check, however professional it looks. The free COA Checker on this site runs the checks for you.
Is Cagrilintide licensed in the UK?
Cagrilintide is Novo Nordisk's amylin analogue. It is not approved in any country, alone or combined with semaglutide as CagriSema, so no UK pharmacy can sell it and every vial on offer is unlicensed research material. The Peptide Watch does not rank or recommend anywhere to buy it, and does not give legal or medical advice.
Why does The Peptide Watch not say where to buy Cagrilintide?
Because the site records paperwork, not recommendations. A verifiable certificate proves that a sample of one batch was tested. It does not prove the vial you receive matches it, and it says nothing about whether you should buy an unlicensed medicine at all. Listing which sellers publish a certificate you can check, and which publish nothing, is as far as the evidence goes.
Cagrilintide in the UK at a glance
| Active UK sellers listing Cagrilintide | 22 |
|---|---|
| Of which publish a verifiable own-name certificate | 4 |
| Of which name no laboratory at all | 6 |
Counted from the vendor ledger at build time. The A-Z directory lists every seller and what each publishes instead.
The Peptide Watch's position on Cagrilintide
Cagrilintide is a regulated medicine. The Peptide Watch audits research-peptide sellers and does not rank or recommend anywhere to buy Cagrilintide; this page exists so the verification standard is clear. If you can verify a seller's testing, you can at least judge its evidence; if you cannot, you are trusting marketing on a regulated medicine sold outside its licensed supply chain. See how UK research-peptide testing stacks up in the market statistics.
Research-use-only information, not medical, dosing or purchasing advice. The Peptide Watch sells nothing and links to no seller. A certificate proves a sample was tested once, not that a specific vial matches it.